PDF herunterladen
CC BY-NC-ND 4.0 · Geburtshilfe Frauenheilkd 2023; 83(03): 299-309
DOI: 10.1055/a-2018-9184
GebFra Science
Review

Update Mammakarzinom 2022 Teil 6 – Brustkrebs in fortgeschrittenen Krankheitsstadien

Artikel in mehreren Sprachen: English | deutsch
Diana Lüftner
1   Immanuel Hospital Märkische Schweiz, Buckow; Medical University of Brandenburg Theodor-Fontane, Brandenburg, Germany
,
Michael P. Lux
2   Klinik für Gynäkologie und Geburtshilfe, Frauenklinik St. Louise, Paderborn, St. Josefs-Krankenhaus, Salzkotten, St. Vincenz Krankenhaus GmbH, Paderborn, Germany
,
Tanja N. Fehm
3   Department of Gynecology and Obstetrics, University Hospital Düsseldorf, Düsseldorf, Germany
,
Manfred Welslau
4   Onkologie Aschaffenburg, Aschaffenburg, Germany
,
Volkmar Müller
5   Department of Gynecology, Hamburg-Eppendorf University Medical Center, Hamburg, Germany
,
Florian Schütz
6   Gynäkologie und Geburtshilfe, Diakonissen-Stiftungs-Krankenhaus Speyer, Speyer, Germany
,
Peter A. Fasching
7   Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
,
Wolfgang Janni
8   Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany
,
Christoph Thomssen
9   Department of Gynaecology, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany
,
Isabell Witzel
5   Department of Gynecology, Hamburg-Eppendorf University Medical Center, Hamburg, Germany
,
Milena Beierlein
7   Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
,
Erik Belleville
10   ClinSol GmbH & Co. KG, Würzburg, Germany
,
Michael Untch
11   Clinic for Gynecology and Obstetrics, Breast Cancer Center, Gynecologic Oncology Center, Helios Klinikum Berlin Buch, Berlin, Germany
,
Marc Thill
12   Agaplesion Markus Krankenhaus, Department of Gynecology and Gynecological Oncology, Frankfurt, Germany
,
Nina Ditsch
13   Department of Gynecology and Obstetrics, University Hospital Augsburg, Augsburg, Germany
,
Bahriye Aktas
14   Department of Gynecology, University of Leipzig Medical Center, Leipzig, Germany
,
Maggie Banys-Paluchowski
15   Department of Gynecology and Obstetrics, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany
,
Cornelia Kolberg-Liedtke
16   Department of Gynecology and Obstetrics, University Hospital Essen, Essen, Germany
,
Achim Wöckel
17   Department of Gynecology and Obstetrics, University Hospital Würzburg, Würzburg, Germany
,
Hans-Christian Kolberg
18   Department of Gynecology and Obstetrics, Marienhospital Bottrop, Bottrop, Germany
,
Nadia Harbeck
19   Breast Center, Department of Gynecology and Obstetrics and CCC Munich LMU, LMU University Hospital, Munich, Germany
,
Elmar Stickeler
20   Department of Obstetrics and Gynecology, Center for Integrated Oncology (CIO Aachen, Bonn, Cologne, Düsseldorf), University Hospital of RWTH Aachen, Aachen, Germany
,
Hans Tesch
21   Oncology Practice at Bethanien Hospital, Frankfurt am Main, Germany
,
Andreas D. Hartkopf
8   Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Zusammenfassung

Die in den letzten Jahren begonnenen großen Studienprogramme zu den CDK4/6-Inhibitoren, den zielgerichteten Therapien und den Antikörper-Medikament-Konjugaten resultieren in Ergebnisse, die von aktuellen Studien auf internationalen Kongressen und Fachzeitschriften veröffentlicht werden. In diesem Zusammenhang sind neue Ergebnisse der großen CDK4/6-Inhibitor-Studien verfügbar. Auch werden zunehmend Daten von großen genomischen Studien zu Effektivitäts- und Resistenzmechanismen für Patientinnen, die mit CDK4/6-Inhibitoren behandelt worden sind, veröffentlicht. Basierend auf diesen Ergebnissen sollten nicht zuletzt Studien in Bezug auf Kombinationspartner und Therapiesequenzen geplant werden. Mit Sacituzumab Govitecan ist aufgrund neuester Veröffentlichungen nun ein zweites Antikörper-Medikament-Konjugat vorhanden, das bei hormonrezeptorpositiven (HRpos)/HER2-negativen (HER2neg) Patientinnen einen Gesamtüberlebensvorteil mit sich bringt. Diese Übersichtsarbeit fasst die neuesten Entwicklungen zusammen und ordnet sie in den aktuellen Forschungsstand ein.

Schlüsselwörter

fortgeschrittener Brustkrebs - Chemotherapie - Therapiestandard


Publikationsverlauf

Eingereicht: 27. November 2022

Angenommen nach Revision: 23. Januar 2023

Artikel online veröffentlicht:
09. März 2023

© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References/Literatur

  • 1 Slamon DJ, Neven P, Chia S. et al. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival. Ann Oncol 2021; 32: 1015-1024
    CrossrefPubMedSuche in Google Scholar
  • 2 Goetz MP, Toi M, Campone M. et al. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol 2017; 35: 3638-3646
    CrossrefPubMedSuche in Google Scholar
  • 3 Slamon DJ, Neven P, Chia S. et al. Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. J Clin Oncol 2018; 36: 2465-2472
    CrossrefPubMedSuche in Google Scholar
  • 4 Sledge jr. GW, Toi M, Neven P. et al. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. J Clin Oncol 2017; 35: 2875-2884
    CrossrefPubMedSuche in Google Scholar
  • 5 Turner NC, OʼLeary B, Cutts R. et al. Genetic landscape of resistance to CDK4/6 inhibition in circulating tumor DNA (ctDNA) analysis of the PALOMA3 trial of palbociclib and fulvestrant versus placebo and fulvestrant. J Clin Oncol 2018; 36 (Suppl.) Abstr.. 1001
    CrossrefPubMedSuche in Google Scholar
  • 6 Sledge jr. GW, Toi M, Neven P. et al. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial. JAMA Oncol 2019;
    CrossrefPubMedSuche in Google Scholar
  • 7 Cristofanilli M, Turner NC, Bondarenko I. et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol 2016; 17: 425-439
    CrossrefPubMedSuche in Google Scholar
  • 8 Tripathy D, Im SA, Colleoni M. et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol 2018;
    CrossrefPubMedSuche in Google Scholar
  • 9 Finn RS, Martin M, Rugo HS. et al. Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med 2016; 375: 1925-1936
    CrossrefPubMedSuche in Google Scholar
  • 10 Hortobagyi GN, Stemmer SM, Burris HA. et al. Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. N Engl J Med 2022; 386: 942-950
    CrossrefPubMedSuche in Google Scholar
  • 11 Hortobagyi GN, Stemmer SM, Burris HA. et al. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med 2016; 375: 1738-1748
    CrossrefPubMedSuche in Google Scholar
  • 12 Im SA, Lu YS, Bardia A. et al. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. N Engl J Med 2019; 381: 307-316
    CrossrefPubMedSuche in Google Scholar
  • 13 Slamon DJ, Neven P, Chia S. et al. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. N Engl J Med 2020; 382: 514-524
    CrossrefPubMedSuche in Google Scholar
  • 14 Turner NC, Ro J, Andre F. et al. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med 2015; 373: 209-219
    CrossrefPubMedSuche in Google Scholar
  • 15 Turner NC, Slamon DJ, Ro J. et al. Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. N Engl J Med 2018; 379: 1926-1936
    CrossrefPubMedSuche in Google Scholar
  • 16 Luftner D, Schutz F, Stickeler E. et al. Update Breast Cancer 2021 Part 5 – Advanced Breast Cancer. Geburtshilfe Frauenheilkd 2022; 82: 215-225
    Thieme ConnectPubMedSuche in Google Scholar
  • 17 Goetz MP, Toi M, Huober J. et al. MONARCH 3: Interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2- advanced breast cancer (ABC). Ann Oncol 2022; 33 (Suppl. 07) S808-S869
    CrossrefPubMedSuche in Google Scholar
  • 18 European Medicines Agency. Verzenios. 2022. Accessed November 20, 2022 at: https://www.emaeuropa.eu/en/medicines/human/summaries-opinion/verzenios
    PubMed
  • 19 Allison KH, Hammond MEH, Dowsett M. et al. Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. J Clin Oncol 2020; 38: 1346-1366
    CrossrefPubMedSuche in Google Scholar
  • 20 Wang J, Li Q, Yuan J. et al. CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest. J Transl Med 2017; 15: 127
    CrossrefPubMedSuche in Google Scholar
  • 21 Long F, He Y, Fu H. et al. Preclinical characterization of SHR6390, a novel CDK 4/6 inhibitor, in vitro and in human tumor xenograft models. Cancer Sci 2019; 110: 1420-1430
    CrossrefPubMedSuche in Google Scholar
  • 22 Xu B, Zhang Q, Zhang P. et al. Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial. Nat Med 2021; 27: 1904-1909
    CrossrefPubMedSuche in Google Scholar
  • 23 Xu B, Zhang QY, Zhang P. et al. Dalpiciclib plus letrozole or anastrozole as first-line treatment for HR+/HER2- advanced breast cancer (DAWNA-2): A phase III trial. Ann Oncol 2022; 33 (Suppl. 07) S808-S869
    CrossrefPubMedSuche in Google Scholar
  • 24 Bidard FC, Hardy-Bessard AC, Dalenc F. et al. Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol 2022; 23: 1367-1377
    CrossrefPubMedSuche in Google Scholar
  • 25 Laine M, Fanning SW, Chang YF. et al. Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer. Breast Cancer Res 2021; 23: 54
    CrossrefPubMedSuche in Google Scholar
  • 26 Andreano KJ, Baker JG, Park S. et al. The Dysregulated Pharmacology of Clinically Relevant ESR1 Mutants is Normalized by Ligand-activated WT Receptor. Mol Cancer Ther 2020; 19: 1395-1405
    CrossrefPubMedSuche in Google Scholar
  • 27 Goetz MP, Plourde P, Stover DG. et al. Open-label, randomized study of lasofoxifene (LAS) vs. fulvestrant (Fulv) for women with locally advanced/metastatic ER+/HER2- breast cancer (mBC), an estrogen receptor 1 (ESR1) mutation, and disease progression on aromatase (AI) and cyclin-dependent kinase 4/6 (CDK4/6i) inhibitors. Ann Oncol 2022; 33 (Suppl. 07) S808-S869
    CrossrefPubMedSuche in Google Scholar
  • 28 Safonov A, Bandlamudi C, Tallón de Lara P. et al. Comprehensive genomic profiling of patients with breast cancer identifies germline-somatic interactions mediating therapy resistanc. San Antonio Breast Cancer Symposium 2021; 2021: GS4-08
    PubMedSuche in Google Scholar
  • 29 Marra A, Gazzo A, Gupta A. et al. Mutational signature analysis reveals patterns of genomic instability linked to resistance to endocrine therapy (ET) ± CDK 4/6 inhibition (CDK4/6i) in estrogen receptor-positive/HER2-negative (ER+/HER2-) metastatic breast cancer (MBC). Ann Oncol 2022; 33 (Suppl. 07) S88-S121
    CrossrefPubMedSuche in Google Scholar
  • 30 Alexandrov LB, Stratton MR. Mutational signatures: the patterns of somatic mutations hidden in cancer genomes. Curr Opin Genet Dev 2014; 24: 52-60
    CrossrefPubMedSuche in Google Scholar
  • 31 Alexandrov LB, Kim J, Haradhvala NJ. et al. The repertoire of mutational signatures in human cancer. Nature 2020; 578: 94-101
    CrossrefPubMedSuche in Google Scholar
  • 32 COSMIC. Mutational Signatures (v3.3 – June 2022)- Single Base Substitution (SBS) Signatures. 2022. Accessed November 12, 2022 at: https://cancer.sanger.ac.uk/signatures/sbs/
    PubMed
  • 33 clinicaltrials.gov. Comprehensive Analysis of Spatial, Temporal and Molecular Patters of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients (CAPTOR-BC). 2022. Accessed July, 16, 2022 at: https://clinicaltrials.gov/ct2/show/NCT05452213
    PubMed
  • 34 clinicaltrials.gov. Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management (MINERVA). 2022. Accessed June 26, 2022 at: https://clinicaltrials.gov/ct2/show/NCT05362760
    PubMed
  • 35 Bidard FC, Kaklamani VG, Neven P. et al. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. J Clin Oncol 2022; 40: 3246-3256
    CrossrefPubMedSuche in Google Scholar
  • 36 AstraZeneca. Camizestrant significantly improved progression-free survival vs. Faslodex in SERENA-2 Phase II trial in advanced ER-positive breast cancer. 2022. Accessed November 20, 2022 at: https://www.astrazeneca.com/media-centre/press-releases/2022/camizestrant-significantly-improved-progression-free-survival.html
    PubMed
  • 37 Tolaney SM, Chan A, Petrakova K. et al. AMEERA-3, a phase II study of amcenestrant (AMC) versus endocrine treatment of physicianʼs choice (TPC) in patients (pts) with endocrine-resistant ER+/HER2− advanced breast cancer (aBC). Ann Oncol 2022; 33 (Suppl. 07) S80-S121
    CrossrefPubMedSuche in Google Scholar
  • 38 Jimenez MM, Lim E, Gregor MCM. et al. Giredestrant (GDC-9545) vs. physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2– locally advanced/metastatic breast cancer (LA/mBC): Primary analysis of the phase II, randomised, open-label acelERA BC study. Ann Oncol 2022; 33 (Suppl. 07) S808-S869
    CrossrefPubMedSuche in Google Scholar
  • 39 Sanofi. Sanofi provides update on amcenestrant clinical development program. 2022. Accessed November 03, 2022 at: https://www.sanofi.com/en/media-room/press-releases/2022/2022-08-17-05-30-00-2499668
    PubMed
  • 40 Di Cosimo S, Perez-Garcia JM, Bellet M. et al. Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial. Oncologist 2023; 28: 23-32
    CrossrefPubMedSuche in Google Scholar
  • 41 Ruiz-Borrego M, Guerrero-Zotano A, Bermejo B. et al. Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2-) early breast cancer (EBC): results from the GEICAM/2006-10 study. Breast Cancer Res Treat 2019; 177: 115-125
    CrossrefPubMedSuche in Google Scholar
  • 42 Rugo HS, Bardia A, Marmé F. et al. Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physicianʼs choice (TPC) in patients (Pts) with hormone receptor–positive/HER2-negative (HR+/HER2-) advanced breast cancer. J Clin Oncol 2022; 40: LBA1001-LBA1001
    CrossrefPubMedSuche in Google Scholar
  • 43 Rugo HS, Bardia A, Marmé F. et al. Overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs. treatment of physicianʼs choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC). Ann Oncol 2022; 33 (Suppl. 07) S808-S869
    CrossrefPubMedSuche in Google Scholar
  • 44 Engler T, Fasching PA, Luftner D. et al. Implementation of CDK4/6 Inhibitors and its Influence on the Treatment Landscape of Advanced Breast Cancer Patients – Data from the Real-World Registry PRAEGNANT. Geburtshilfe Frauenheilkd 2022; 82: 1055-1067
    Thieme ConnectPubMedSuche in Google Scholar
  • 45 Hartkopf A. Therapy landscapes and molecular markers, the German PRAEGNANT registry. ESMO Breast Cancer Conference 2022. 2022. Accessed November 10, 2022 at: https://oncologypro.esmo.org/meeting-resources/esmo-breast-cancer-congress/therapy-landscapes-and-molecular-markers-the-german-praegnant-registry
    PubMed
  • 46 Modi S, Jacot W, Yamashita T. et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med 2022; 387: 9-20
    CrossrefPubMedSuche in Google Scholar
  • 47 Rugo HS, Bardia A, Marme F. et al. Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer. J Clin Oncol 2022; 40: 3365-3376
    CrossrefPubMedSuche in Google Scholar
  • 48 Emens LA, Middleton G. The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol Res 2015; 3: 436-443
    CrossrefPubMedSuche in Google Scholar
  • 49 Opzoomer JW, Sosnowska D, Anstee JE. et al. Cytotoxic Chemotherapy as an Immune Stimulus: A Molecular Perspective on Turning Up the Immunological Heat on Cancer. Front Immunol 2019; 10: 1654
    CrossrefPubMedSuche in Google Scholar
  • 50 Munzone E, Regan MM, Cinieri S. et al. A randomized phase II trial of metronomic oral vinorelbine plus cyclophosphamide and capecitabine (VEX) vs. weekly paclitaxel (P) as first- or second-line treatment in patients (pts) with ER+/HER2- metastatic breast cancer (MBC): The METEORA-II trial (IBCSG 54-16). Ann Oncol 2022; 33 (Suppl. 07) S88-S121
    CrossrefPubMedSuche in Google Scholar
  • 51 clinicaltrials.gov. NCT05033769. Assessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast Cancer (AIRE). NIH US National Library of Medicine 2022; Zugriff am 01. November 2022 unter: https://clinicaltrials.gov/ct2/show/NCT05033769
  • 52 Janni W, Schneeweiss A, Muller V. et al. Update Breast Cancer 2019 Part 2 – Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical Practice. Geburtshilfe Frauenheilkd 2019; 79: 268-280
    Thieme ConnectPubMedSuche in Google Scholar
  • 53 OʼBrien NA, McDonald K, Tong L. et al. Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT. Clin Cancer Res 2014; 20: 3507-3520
    CrossrefPubMedSuche in Google Scholar
  • 54 Loibl S, von Minckwitz G, Schneeweiss A. et al. PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer. J Clin Oncol 2014; 32: 3212-3220
    CrossrefPubMedSuche in Google Scholar
  • 55 Schlam I, Tarantino P, Tolaney SM. Overcoming Resistance to HER2-Directed Therapies in Breast Cancer. Cancers (Basel) 2022; 14: 3996
    CrossrefPubMedSuche in Google Scholar
  • 56 Xu B, Yan M, Ma F. et al. Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer (PHILA): A randomized phase III trial. Ann Oncol 2022; 33 (Suppl. 07) S808-S869
    CrossrefPubMedSuche in Google Scholar
  • 57 Swain SM, Baselga J, Kim SB. et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 2015; 372: 724-734
    CrossrefPubMedSuche in Google Scholar
  • 58 Baselga J, Cortes J, Kim SB. et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012; 366: 109-119
    CrossrefPubMedSuche in Google Scholar
  • 59 Muller V, Welslau M, Luftner D. et al. Update Breast Cancer 2022 Part 2 – Advanced Stage Breast Cancer. Geburtshilfe Frauenheilkd 2022; 82: 590-600
    Thieme ConnectPubMedSuche in Google Scholar
  • 60 Aktas B, Fehm TN, Welslau M. et al. Update Breast Cancer 2022 Part 4 – Advanced-Stage Breast Cancer. Geburtshilfe Frauenheilkd 2022; 82: 922-931
    Thieme ConnectPubMedSuche in Google Scholar
  • 61 Ditsch N, Stickeler E, Behrens A. et al. Update Breast Cancer 2021 Part 2 – Advanced Stages, Long-Term Consequences and Biomarkers. Geburtshilfe Frauenheilkd 2021; 81: 539-548
    Thieme ConnectPubMedSuche in Google Scholar
  • 62 Tesch H, Muller V, Wockel A. et al. Update Breast Cancer 2020 Part 4 – Advanced Breast Cancer. Geburtshilfe Frauenheilkd 2020; 80: 1115-1122
    Thieme ConnectPubMedSuche in Google Scholar
  • 63 André F, Nadal JC, Denys H. et al. Final overall survival (OS) for abemaciclib plus trastuzumab ± fulvestrant versus trastuzumab plus chemotherapy in patients with HR+, HER2+ advanced breast cancer (monarcHER): A randomized, open-label, phase II trial. Ann Oncol 2022; 33 (Suppl. 07) S808-S869
    CrossrefPubMedSuche in Google Scholar